share_log

Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight

Benzinga ·  Dec 10, 2024 21:55

Cantor Fitzgerald analyst Charles Duncan reiterates Stoke Therapeutics (NASDAQ:STOK) from Overweight to Overweight.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment